anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. (Q38207759)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

title

anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

0 references

0 references

0 references

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Roberto Caporali

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Giovanni Lapadula

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Andrea Marcellusi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Carlo Salvarani

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

author name string

A Armuzzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

P Lionetti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

S Chimenti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

L Cimino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

P Gionchetti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

G Girolomoni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

A Marchesoni

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

F S Mennini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

R Cimaz

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

publication date

1 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Immunopathology and Pharmacology

16 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

issue

1 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

page(s)

11-32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002.

16 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Pathogenesis of myocarditis and dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Human antibody-Fc receptor interactions illuminated by crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

The interactions of therapeutic antibodies with Fc receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Etanercept in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Indirect comparison of biological treatments in refractory rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

What factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

How do patients with inflammatory bowel disease want their biological therapy administered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab in active ulcerative colitis: a "real-life" observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Tight control applied to the biological therapy of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

[How early would we really administer biologics?].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

The British Society for Rheumatology Biologics Register: 6 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F03946320140270S102

10.1177/03946320140270S102

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24774504%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

1 reference